PrimeC Market Summary

Key Factors Driving PrimeC Growth

1. Strong Clinical Efficacy Signals in ALS

• PrimeC is an extended-release oral fixed-dose combination of ciprofloxacin and celecoxib developed by NeuroSense Therapeutics to address multiple pathological mechanisms in amyotrophic lateral sclerosis (ALS), such as neuroinflammation, iron dysregulation, and miRNA dysfunction.
• In the Phase IIb PARADIGM trial, PrimeC demonstrated statistically significant slowing of ALS progression and survival benefits: progression slowed by ~33–37% versus placebo, with improved survival in treated patients.

2. Orphan Drug Designation and Regulatory Support

• PrimeC has received Orphan Drug Designation from both the US FDA and the European Medicines Agency, which can provide incentives such as fee waivers, protocol assistance, and market exclusivity (e.g., 7 years in the US and 10 years in Europe upon approval).
• The US FDA has authorized a pivotal Phase III trial (PARAGON), planned to enroll ~300 ALS participants following positive Phase IIb feedback a key step toward potential approval.

3. Strategic Partnerships and Development Support

• NeuroSense has signed a binding term sheet with a global pharmaceutical partner to accelerate Phase III development and commercialization, including upfront funding, milestone payments, and tiered royalties on annual net sales.
• A partnership with Recipharm supports advanced formulation and commercial-scale manufacturing, overcoming formulation challenges for the fixed-dose PrimeC tablet.

4. Commercial Manufacturing Scale-Up and Market Preparation

• NeuroSense has successfully scaled up commercial manufacturing of PrimeC and qualified supply chains for both active ingredients with validated analytical methods and stability supporting a 36-month shelf life at room temperature.
• The company is pursuing early market entry in Canada through Health Canada’s Notice of Compliance with Conditions (NOC/c) pathway, which could enable accelerated access for ALS patients prior to broader approvals.

5. Expanded Disease Potential Beyond ALS

• Analyses of plasma samples from the Phase IIb PARADIGM trial show that PrimeC significantly reduces Alzheimer’s disease-associated microRNAs linked to neuroinflammation and amyloid/tau pathology, providing mechanistic rationale for future Alzheimer’s disease (AD) development.
• These findings suggest PrimeC could be studied in AD clinical programs, vastly expanding its addressable market beyond ALS into one of the largest global therapeutic markets.

PrimeC Recent Developments

• In February 2026, NeuroSense Therapeutics Ltd., a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, announced the availability of additional long-term survival data from its previously completed PARADIGM Phase IIb clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).
• In September 2025, Recipharm, a leading global contract development and manufacturing organization (CDMO) partnered with NeuroSense Therapeutics to develop PrimeC, an advanced fixed-dose combination tablet designed to target multiple disease mechanisms in Amyotrophic Lateral Sclerosis (ALS). 

“PrimeC Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of PrimeC for potential indication like Amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease in the 7MM. A detailed picture of PrimeC’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the PrimeC for potential indications. The PrimeC market report provides insights about PrimeC’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current PrimeC performance, future market assessments inclusive of the PrimeC market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of PrimeC sales forecasts, along with factors driving its market.

 

PrimeC Drug Summary

PrimeC is a proprietary, extended-release oral fixed-dose combination therapy developed by NeuroSense Therapeutics, consisting of ciprofloxacin (an antibiotic) and celecoxib (a COX-2 inhibitor) in a patented synchronized matrix formulation that optimizes coordinated delivery to target multiple ALS pathological pathways simultaneously, including neuroinflammation, iron accumulation in motor neurons, microRNA dysregulation, and TDP-43 protein aggregation. Designed as a potential disease-modifying treatment for amyotrophic lateral sclerosis (ALS), it demonstrated significant efficacy in the Phase IIb PARADIGM trial (n=68, randomized 2:1 vs. placebo), achieving 33% functional improvement (ALSFRS-R slope difference of ~8 points over 18 months, p=0.007), 58% better survival rates, slowed respiratory decline, and biomarker changes (e.g., reduced NfL, chitinase-3-like protein 1), with a favorable safety profile in over 70 patients across Phase IIa/IIb studies. The report provides PrimeC’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the PrimeC Market Report

The report provides insights into:

• A comprehensive product overview including the PrimeC MoA, description, dosage and administration, research and development activities in potential indication like Amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease.
• Elaborated details on PrimeC regulatory milestones and other development activities have been provided in PrimeC market report.
• The report also highlights PrimeC‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The PrimeC market report also covers the patents information, generic entry and impact on cost cut.
• The PrimeC market report contains current and forecasted PrimeC sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The PrimeC market report also features the SWOT analysis with analyst views for PrimeC in potential indications.

 

Methodology

The PrimeC market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

PrimeC Analytical Perspective by DelveInsight

In-depth PrimeC Market Assessment

This PrimeC sales market forecast report provides a detailed market assessment of PrimeC for potential indication like Amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted PrimeC sales data uptil 2034.

 

PrimeC Clinical Assessment

The PrimeC market report provides the clinical trials information of PrimeC for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

PrimeC Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

 

PrimeC Market Potential & Revenue Forecast

• Projected market size for the PrimeC and its key indications
• Estimated PrimeC sales potential (PrimeC peak sales forecasts)
• PrimeC Pricing strategies and reimbursement landscape

 

PrimeC Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• PrimeC Market positioning compared to existing treatments
• PrimeC Strengths & weaknesses relative to competitors

 

PrimeC Regulatory & Commercial Milestones

• PrimeC Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

PrimeC Clinical Differentiation

• PrimeC Efficacy & safety advantages over existing drugs
• PrimeC Unique selling points

 

PrimeC Market Report Highlights

• In the coming years, the PrimeC market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The PrimeC companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PrimeC’s dominance.
• Other emerging products for corneal disorders are expected to give tough market competition to PrimeC and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PrimeC in potential indications.
• Analyse PrimeC cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted PrimeC sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of PrimeC in potential indications.

 

Key Questions Answered In The PrimeC Market Report

• What is the class of therapy, route of administration and mechanism of action of PrimeC? How strong is PrimeC’s clinical and commercial performance?
• What is PrimeC’s clinical trial status in each individual indications such as Amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PrimeC Manufacturers?
• What are the key designations that have been granted to PrimeC for potential indications? How are they going to impact PrimeC’s penetration in various geographies?
• What is the current and forecasted PrimeC market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of PrimeC in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to PrimeC for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is PrimeC? What is the duration of therapy and what are the geographical variations in cost per patient?